847 articles with Bayer
Fruit Logistica 2023: Bayer Focuses on Partnerships, Sustainability, and Innovation
At this year's Fruit Logistica taking place in Berlin from February 8-10 Bayer highlights its solutions towards regenerative agriculture, meaning the balance between productivity outcomes and environmental protection, while supporting the needs of society and farmers.
Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer
Bayer further expands the global clinical development program for NUBEQA® (darolutamide) in prostate cancer.
Darolutamide approved for additional prostate cancer indication in China
The Chinese National Medical Products Administration has approved the oral androgen receptor inhibitor darolutamide in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Bayer and Kimitec Join Forces To Bring the Next Generation of Biologicals to Millions of Growers Worldwide
Bayer and Kimitec announced a new strategic partnership focused on accelerating the development and commercialization of biological crop protection solutions and biostimulants.
Bayer plans to substantially increase investment in U.S.-based pharmaceutical R&D, earmarking $1 billion to invest stateside in 2023.
AskBio Announces Gustavo Pesquin as New CEO
Asklepios BioPharmaceutical, Inc., a wholly owned and independently operated subsidiary of Bayer AG, announced that Gustavo Pesquin will become the company's next Chief Executive Officer as of March 11, 2023.
Bayer To Distribute Pheromone-Based Biological Crop Protection Solutions From M2i Group
Bayer announced a partnership with French company M2i Group to supply fruit and vegetable growers around the world with pheromone-based biological crop protection products.
Darolutamide receives EU approval for additional indication in prostate cancer
The European Commission has granted marketing authorisation in the European Union for darolutamide, an oral androgen receptor inhibitor, plus androgen deprivation therapy in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Amid mounting pressure from investors and shareholders, Bayer’s supervisory board unanimously appointed outsider Bill Anderson as its new CEO.
Bayer Announces First Patients Enrolled in Global Phase III Studies for Investigational Oral FXIa Inhibitor Asundexian
Bayer today announced the first patients have been enrolled in the initial trials for its OCEANIC clinical trial program, designed to explore the use of asundexian (BAY2433334).
Bayer Announces Full Commercialization of ThryvOn™ Technology in the U.S., a Unique Cotton Biotech Trait Set to Launch for 2023 Growing Season
In time for the 2023 cotton planting season, Bollgard® 3 ThryvOn™ cotton with XtendFlex® Technology is now commercially available.
Bayer Appoints Ben Kampelman as Vice President of Communications for Crop Science North America
Bayer today announced that Ben Kampelman, formerly Director, Strategic Communications for Crop Science North America, has been appointed to the role of Vice President of Communications, Crop Science North America.
Bayer Acquires Blackford Analysis Ltd. Bolstering the Company’s Position in Digital Medical Imaging
Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd.
Evogene to Receive $3.5 million Payment Related to Patent Portfolio under its Existing Seed Traits Collaboration with Bayer
Evogene Ltd. announced today that Bayer will pay Evogene an amount of $3.5 million under their joint seed traits collaboration agreement.
Bayer Launches Industry-First Public Database Listing Company’s Science Collaborations and Partnerships in the U.S.
Bayer announced the U.S. launch of the Bayer Science Collaboration Explorer as part of its ongoing efforts to enhance public trust in scientific innovations, processes, and R&D activities.
New research out of McMaster University found a recently abandoned Bayer compound halted the growth of an aggressive form of pediatric medulloblastoma in mouse models.
Bayer Signs Grant Agreement to Advance Research in Non-Hormonal Contraception
Bayer announced today that it has received a grant from the Bill & Melinda Gates Foundation.
Outside the US Bayer Extends Development Program for Investigational Product Elinzanetant With Phase III Study in Breast Cancer Patients With Vasomotor Symptoms Caused by Endocrine Therapy
Bayer, a global leader in women’s healthcare, announced that it will extend the Phase III clinical development program OASIS by initiating OASIS 4 – a Phase III non-US study in breast cancer patients and women at risk for breast cancer with vasomotor symptoms caused by endocrine therapy.
In spite of positive Phase IIb results from a thrombosis prevention trial, Ionis is back on the market for a new partner after Bayer returned the rights to the drug to Ionis.
Bayer to Highlight Additional Analyses From Comprehensive KERENDIA® (finerenone) Clinical Trial Program at the American Society of Nephrology’s 2022 Kidney Week
Bayer will present data from the comprehensive KERENDIA® (finerenone) clinical trial program, conducted in patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D), at the American Society of Nephrology’s (ASN) Kidney Week 2022, scientific sessions and exchange, from November 3-6.